• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    3/27/23 1:31:06 PM ET
    $ALIM
    $AZYO
    $CYCN
    $DCTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Health Care
    Get the next $ALIM alert in real time by email

    Gainers

    • Alimera Sciences (NASDAQ:ALIM) shares moved upwards by 33.2% to $1.8 during Monday's regular session. As of 13:30 EST, this security is trading at a volume of 419.3K shares, making up 3567.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.6 million.
    • Pyxis Oncology (NASDAQ:PYXS) shares increased by 24.05% to $2.74. Trading volume for this security as of 13:30 EST is 29.2 million, which is 19761.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $101.3 million. As per the news, the Q4 earnings report came out 3 days ago.
    • Delcath Systems (NASDAQ:DCTH) shares increased by 23.96% to $6.0. Trading volume for this security as of 13:30 EST is 460.3K, which is 1607.9% of its average full-day volume over the last 100 days. The company's market cap stands at $60.2 million. The company's, Q4 earnings came out today.
    • Aziyo Biologics (NASDAQ:AZYO) shares moved upwards by 23.73% to $1.82. As of 13:30 EST, this security is trading at a volume of 960.0K shares, making up 458.8% of its average full-day volume over the last 100 days. The company's market cap stands at $29.4 million. The company's, Q4 earnings came out 3 days ago.
    • Jounce Therapeutics (NASDAQ:JNCE) stock increased by 21.85% to $1.84. Jounce Therapeutics's stock is trading at a volume of 9.6 million shares as of 13:30 EST. This is 401.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $95.9 million.
    • Cyclerion Therapeutics (NASDAQ:CYCN) shares moved upwards by 19.7% to $0.52. Trading volume for this security as of 13:30 EST is 9.0 million, which is 7986.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $22.7 million. The company's, Q4 earnings came out 3 days ago.

    Losers

    • Unity Biotechnology (NASDAQ:UBX) shares decreased by 50.9% to $2.04 during Monday's regular session. Unity Biotechnology's stock is trading at a volume of 5.0 million shares as of 13:30 EST. This is 2049.2% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $29.2 million.
    • Sonnet BioTherapeutics (NASDAQ:SONN) shares declined by 45.74% to $0.33. The current volume of 1.8 million shares is 405.4% of Sonnet BioTherapeutics's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $6.6 million.
    • NuCana (NASDAQ:NCNA) stock decreased by 34.76% to $0.81. The current volume of 741.3K shares is 536.0% of NuCana's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $42.2 million.
    • Pharming (NASDAQ:PHAR) stock fell 18.87% to $12.14. Trading volume for Pharming's stock is 202.5K as of 13:30 EST. This is 1170.0% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $791.8 million.
    • Timber Pharmaceuticals (AMEX:TMBR) shares declined by 16.67% to $1.75. Trading volume for this security as of 13:30 EST is 352.4K, which is 32.7% of its average full-day volume over the last 100 days. The company's market cap stands at $5.2 million.
    • SCYNEXIS (NASDAQ:SCYX) stock fell 15.5% to $1.58. Trading volume for this security as of 13:30 EST is 366.9K, which is 92.8% of its average full-day volume over the last 100 days. The company's market cap stands at $51.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALIM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALIM
    $AZYO
    $CYCN
    $DCTH

    CompanyDatePrice TargetRatingAnalyst
    Pyxis Oncology Inc.
    $PYXS
    11/3/2025$9.00Buy
    Stifel
    Pyxis Oncology Inc.
    $PYXS
    9/4/2025$5.00Buy
    Guggenheim
    Unity Biotechnology Inc.
    $UBX
    5/27/2025$2.00Buy → Neutral
    H.C. Wainwright
    Unity Biotechnology Inc.
    $UBX
    5/16/2025$6.00 → $1.00Outperform → Neutral
    Mizuho
    Pharming Group N.V. ADS each representing 10
    $PHAR
    12/9/2024$14.00Buy
    Jefferies
    Pyxis Oncology Inc.
    $PYXS
    11/21/2024Outperform → Mkt Perform
    William Blair
    Pyxis Oncology Inc.
    $PYXS
    11/8/2024$13.00Overweight
    Stephens
    NuCana plc
    $NCNA
    8/30/2024Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $ALIM
    $AZYO
    $CYCN
    $DCTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update

    SCYNEXIS received a one-time non-refundable payment in Q4 2025 totalling $24.8 million from GSK SCYNEXIS announced dosing of the first patient using the intravenous (IV) formulation of SCY-247 in a Phase 1 study and plans to report topline data in the second half of 2026 Responding to patients' need for alternatives to existing anti-fungal therapies, SCYNEXIS plans to initiate an expanded access program for SCY-247 in the first half of 2026SCYNEXIS ended Q4 2025 with cash, cash equivalents and investments of $56.3 million, resulting in a cash runway of more than two years JERSEY CITY, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneerin

    3/4/26 4:20:00 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology

    Publication Highlights Promise of Combined Percutaneous Hepatic Perfusion and Immunotherapy in Metastatic Uveal Melanoma Delcath Systems, Inc. (NASDAQ:DCTH), ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Principal Investigator Professor Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology. The publication, titled "Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre

    3/3/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

    JERSEY CITY, N.J., Feb. 26, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the first participants have been dosed in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial evaluating the intravenous formulation (IV) of its second-generation triterpenoid antifungal therapy, SCY-247, which is being developed as a treatment for invasive candidiasis (IC) and as a prophylaxis therapy for invasive fungal disease. Results from this trial are expected in 2026. "Following the FDA's recent decision to grant SCY-247 bot

    2/26/26 8:23:29 AM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    $AZYO
    $CYCN
    $DCTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Pennell Sandra bought $50,018 worth of shares (5,533 units at $9.04), increasing direct ownership by 8% to 77,018 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/6/26 4:22:21 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Michel Gerard J bought $100,309 worth of shares (11,200 units at $8.96), increasing direct ownership by 3% to 342,034 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/3/26 4:15:22 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by GM INTERVENTIONAL ONCOLOGY Muir Kevin

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    2/18/26 9:30:13 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $ALIM
    $AZYO
    $CYCN
    $DCTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel resumed coverage on Pyxis Oncology with a new price target

    Stifel resumed coverage of Pyxis Oncology with a rating of Buy and set a new price target of $9.00

    11/3/25 9:08:29 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Pyxis Oncology with a new price target

    Guggenheim initiated coverage of Pyxis Oncology with a rating of Buy and set a new price target of $5.00

    9/4/25 9:07:21 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Unity Biotechnology downgraded by H.C. Wainwright with a new price target

    H.C. Wainwright downgraded Unity Biotechnology from Buy to Neutral and set a new price target of $2.00

    5/27/25 9:09:16 AM ET
    $UBX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    $AZYO
    $CYCN
    $DCTH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-7) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 10/01/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    10/2/24 4:43:10 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-3) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 05/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: Labeling

    5/23/24 10:32:08 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    FDA Approval for HEPZATO issued to DELCATH SYSTEMS INC

    Submission status for DELCATH SYSTEMS INC's drug HEPZATO (SUPPL-4) with active ingredient MELPHALAN HYDROCHLORIDE has changed to 'Approval' on 01/22/2024. Application Category: NDA, Application Number: 201848, Application Classification: REMS

    1/23/24 4:36:46 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $ALIM
    $AZYO
    $CYCN
    $DCTH
    SEC Filings

    View All

    SEC Form 10-K filed by SCYNEXIS Inc.

    10-K - SCYNEXIS INC (0001178253) (Filer)

    3/4/26 4:01:59 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Delcath Systems Inc.

    8-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

    3/3/26 4:48:16 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by Delcath Systems Inc.

    10-K - DELCATH SYSTEMS, INC. (0000872912) (Filer)

    2/26/26 9:15:35 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $ALIM
    $AZYO
    $CYCN
    $DCTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Pennell Sandra bought $50,018 worth of shares (5,533 units at $9.04), increasing direct ownership by 8% to 77,018 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/6/26 4:22:21 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    CHIEF EXECUTIVE OFFICER Michel Gerard J bought $100,309 worth of shares (11,200 units at $8.96), increasing direct ownership by 3% to 342,034 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    3/3/26 4:15:22 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Director Sylvester John Richard bought $38,992 worth of shares (4,386 units at $8.89), increasing direct ownership by 42% to 14,936 units (SEC Form 4)

    4 - DELCATH SYSTEMS, INC. (0000872912) (Issuer)

    11/25/25 4:15:07 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $ALIM
    $AZYO
    $CYCN
    $DCTH
    Leadership Updates

    Live Leadership Updates

    View All

    CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

    SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company pursuing new targets and novel phagocytic mechanism, announces the appointment of Eric Francois to the Company's Board of Directors. "Eric's decades of financial, transactional and operational experience will make an immediate impact to CERo's board of directors," said Chris Ehrlich, Company Chairman and Chief Executive Officer. "Furthermore, his expertise in capital raising, M&A, and business development will be an impactful addition at this stage of our development." Mr. Francois is an executive with over 25

    2/17/26 8:00:00 AM ET
    $CERO
    $CRVO
    $SCYX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

    –Received Positive Pre-Investigational New Drug ("IND") Written Feedback from the U.S. Food and Drug Administration ("FDA")– –Clinical Advisory Board ("CAB") Includes Key Leaders across Neuropsychiatry, Anesthesiology, and Clinical Development– –Remain On Track to Initiate CYC-126's Phase 2 Proof-of-Concept ("POC") Study in Treatment Resistant Depression ("TRD") in the Second Half of 2026– CAMBRIDGE, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) ("Cyclerion" or "Company"), a biopharmaceutical company pioneering neuropsychiatric therapies, today announced it has received positive written regulatory feedback and responses from the FDA on CYC-126

    2/17/26 7:00:00 AM ET
    $CYCN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity

    BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (NASDAQ:PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a leadership transition to continue execution and advancement of the Company's strategic and clinical goals. Thomas Civik, a member of Pyxis Oncology's Board of Directors since the Company's IPO and a highly experienced biotechnology executive with a proven track record in advancing cancer therapeutics, has been appointed Interim Chief Executive Officer, effective immediately. Lara S. Sullivan, M.D., has stepped down from her roles as President, Chief Executive Officer and Chief Medical Officer. With

    2/3/26 6:45:00 AM ET
    $PYXS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALIM
    $AZYO
    $CYCN
    $DCTH
    Financials

    Live finance-specific insights

    View All

    Delcath Systems Reports Fourth Quarter and Full Year 2025 Results

    Conference Call Today at 8:30 a.m. Eastern Time Delcath Systems, Inc. (NASDAQ:DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively HEPZATO KIT™ fourth quarter and full year revenue of $19.0 million and $78.8 million, respectively CHEMOSAT® fourth quarter and full year revenue of $1.7 million and $6.4 million, respectively Gro

    2/26/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12

    Leiden, the Netherlands, February 26, 2026: Pharming Group N.V. ("Pharming" or "the Company") (NASDAQ:PHAR) confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/08:30 am EDT. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration:https://register-conf.media-server.com/register/BIb3649a77439d4a2d8e5e002bac980cd1 Once registered, dial-in information and a unique PIN will

    2/26/26 2:00:00 AM ET
    $PHAR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Delcath Systems to Host Fourth Quarter and Full Year 2025 Earnings Call

    Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Thursday, February 26, 2026 Time: 8:30 AM Eastern Time Participant Numbers: Toll Free: 1-877-407-3982 International: 1-201-493-6780 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1747469&tp_key=15ec7bd15c A replay of the w

    2/12/26 8:00:00 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    $ALIM
    $AZYO
    $CYCN
    $DCTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/15/24 10:33:51 AM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Delcath Systems Inc.

    SC 13D/A - DELCATH SYSTEMS, INC. (0000872912) (Subject)

    11/14/24 9:46:56 PM ET
    $DCTH
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by SCYNEXIS Inc.

    SC 13G/A - SCYNEXIS INC (0001178253) (Subject)

    11/14/24 7:07:26 PM ET
    $SCYX
    Biotechnology: Pharmaceutical Preparations
    Health Care